BIT Share Price

Open 0.04 Change Price %
High 0.04 1 Day 0.00 0.00
Low 0.04 1 Week 0.00 0.00
Close 0.04 1 Month 0.00 0.00
Volume 351000 1 Year -0.04 -50.00
52 Week High 0.08
52 Week Low 0.03
BIT Important Levels
Resistance 2 0.04
Resistance 1 0.04
Pivot 0.04
Support 1 0.04
Support 2 0.04
ASX Australia Most Active Stocks
AGO 0.03 0.00%
AGO 0.03 0.00%
AGO 0.03 0.00%
BUR 0.02 0.00%
BUR 0.02 0.00%
BUR 0.02 0.00%
TLS 4.55 -1.30%
TLS 4.55 -1.30%
TLS 4.55 -1.30%
LYC 0.10 0.00%
More..
ASX Australia Top Gainers Stocks
KSO 0.40 3900.00%
RMG 0.02 100.00%
RMG 0.02 100.00%
PMQ 0.03 50.00%
IRM 0.03 50.00%
IRM 0.03 50.00%
IRM 0.03 50.00%
BNV 0.03 50.00%
AQQ 0.03 50.00%
AQQ 0.03 50.00%
More..
ASX Australia Top Losers Stocks
APP 0.20 -80.00%
APP 0.20 -80.00%
APP 0.20 -80.00%
APP 0.20 -80.00%
ROG 0.01 -80.00%
ROG 0.01 -80.00%
ROG 0.01 -80.00%
TCQ 0.27 -73.53%
GDY 0.01 -50.00%
ODY 0.06 -33.33%
More..

Biotron Ltd (ASX: BIT)

BIT Technical Analysis 2
As on 22nd Mar 2017 BIT Share Price closed @ 0.04 and we RECOMMEND Sell for LONG-TERM with Stoploss of 0.05 & Strong Buy for SHORT-TERM with Stoploss of 0.04 we also expect STOCK to react on Following IMPORTANT LEVELS.
BIT Target for March
1st Target up-side 0.05
2nd Target up-side 0.06
3rd Target up-side 0.07
1st Target down-side 0.03
2nd Target down-side 0.02
3rd Target down-side 0.01
BIT Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.biotron.com.au
BIT Address
BIT
56 Delhi Road
Suite 19
North Ryde, NSW 2113
Australia
Phone: 61 2 9805 0488
Fax: 61 2 9805 0688
BIT Latest News
Interactive Technical Analysis Chart Biotron Ltd ( BIT ASX Australia )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Biotron Ltd
BIT Business Profile
Biotron Limited develops and commercializes novel small molecule antiviral therapeutics targeting Hepatitis C virus (HCV) and HIV-1 in Australia. Its lead drug includes the BIT225, a viroporin inhibitor, which is in Phase 2 clinical trials used for the treatment of HCV and HIV infections. The company also has a portfolio of clinical and preclinical antiviral programs developing drugs targeting HCV, HIV, Dengue virus, and Influenza virus. Biotron Limited is based in North Ryde, Australia.